Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Puma Biotechnology Inc | NERLYNX (Neratinib) monotherapy with high dose loperamide prophylaxis - (CONTROL) | Extended adjuvant treatment of early stage HER2-positive breast cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Puma Biotechnology Inc | NERLYNX (Neratinib) - (SUMMIT) | Metastatic triple negative breast cancer with a HER2 mutation | Phase 2 | Data Released | Oral | Oncology |
| PureTech Health plc | VE303 - (RESTORATiVE303) | Clostridioides difficile infection (CDI) | Phase 3 | Ongoing | oral | Gastroenterology |
| PureTech Health plc | Deupirfenidone (LYT-100) - (SURPASS-IPF) | Idiopathic pulmonary fibrosis (IPF) | Phase 3 | Trial Planned | Oral | Respiratory |
| PureTech Health plc | GlyphAllo (SPT-300) - (BUOY-1) | Major Depressive Disorder | Phase 2b | Enrollment Initiation | oral | Psychiatric |
| PureTech Health plc | VE202 - (COLLECTiVE202) | Ulcerative colitis (UC) | Phase 2 | Data Released | Oral | Gastroenterology |
| PureTech Health plc | VE303 - (CONSORTIUM) | Clostridioides difficile infection (CDI) | Phase 2 | Data Released | oral | Gastroenterology |
| PureTech Health plc | SPT-300 (Glyph allopregnanolone; formerly LYT-300) | Healthy volunteers, neurological and neuropsychological conditions | Phase 2a | Data Released | Oral | Neurology |
